Journal: International Journal of Molecular Sciences

Article Title: Novel Benzoxazoles Containing 4-Amino-Butanamide Moiety Inhibited LPS-Induced Inflammation by Modulating IL-6 or IL-1β mRNA Expression

doi: 10.3390/ijms23105331

Figure Lengend Snippet: Compounds 5f and 4d attenuate inflammation in vitro. Effects of compounds (10 µM) on the protein levels of STAT3, IκB, and NF-κB in AML-12 cells. ( a ) Expression levels of inflammation related-proteins in vitro. ( b – d ) Protein expression levels were normal-ized against the indicated protein. * p < 0.05 compared with the group treated with the PBS (vehicle). + p < 0.05 compared with the group treated with the LPS. Data are pre-sented as the mean ± SD.

Article Snippet: The human keratinocytes HaCaT or the alpha mouse liver 12 (AML-12) cells were obtained from Cell Lines Service GmbH (Eppelheim, Germany).

Techniques: In Vitro, Expressing

Journal: Heliyon

Article Title: Oral administration of kynurenic acid delays the onset of type 2 diabetes in Goto-Kakizaki rats

doi: 10.1016/j.heliyon.2023.e17733

Figure Lengend Snippet: KYNA enhances mRNA and protein expression of hepatic UCP genes. (A, B) Real-time quantitative PCR analysis (n = 6) of gene expression in HepG2 cells after 48 h of 10 μmol/L (K10) or 100 μmol/L (K100) KYNA treatment compared with control group (white punctuated line). (C, D) Western blot analysis of UCP2 expression in HepG2 cells after 48 h of 100 μmol/L KYNA treatment (n = 3), (E, F) Real-time quantitative PCR analysis of gene expression in HepG2 cells after 2 h treatment with 10 μmol/L (K10) or 100 μmol/L (K100) KYNA (n = 6), (G) Quantitative PCR analysis of gene expression in AML-12 cells after 48 h treatment with 10 μmol/L (K10) or 100 μmol/L (K100) KYNA (n = 6), (H) Expression of hepatic energy metabolism genes in GK rats after oral administration 25 mg/kg KYNA (KYNA) or NaCl (Ctrl) (I) Comprehensive analysis of transcriptomic pathways in KYNA-treated HepG2 cells after 48 h KYNA, 100 μmol/L (n = 3). Statistical analysis using t -test, * p < 0.05.

Article Snippet: HepG2 human liver cells and AML-12 mouse liver cells (Procell, China) were cultured in MEM basal medium (Gibco, China) containing 10% fetal bovine plasma (Gibco, Australia).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot

Journal: International Journal of Stem Cells

Article Title: Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia

doi: 10.15283/ijsc21083

Figure Lengend Snippet: The effects of peptide targeted FLT-4 in leukemic mouse model. (A) Expressions of NK cells and IFN-γ of NK cells in BM after single, double, and triple treatments (n=12). (B) Expressions of NK cells and IFN-γ of NK cells in spleen after single, double, and triple treatments (n=12). (C) Expressions of NK cells and IFN-γ of NK cells in liver after single, double, and triple treatments. Bars represent an average (mean)±SE and Asterisks depict statistically significant differences compared to C1498 injected groups (*p<0.05 vs. C1498 injected group, n=12). WT: wild type, C1498: C1498 injected, P: peptide, M: MAZ51, A: ara-C.

Article Snippet: The murine myeloid leukemia cell line C1498 (a murine AML cell line, TIB-49; ATCC, Manassas, VA, USA) was used.

Techniques: Injection

Journal: International Journal of Stem Cells

Article Title: Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia

doi: 10.15283/ijsc21083

Figure Lengend Snippet: The effects of peptide targeted FLT-4 in AML mouse model. The transcriptional level of cytolytic factors including LAMP1, perforin, granzyme B, and IFN-γ displayed in spleen and liver. Bars represent an average (mean)±SE and Asterisks depict statistically significant differences compared to C1498 injected groups. Data shown represent the means of independent experiment with duplicate (*p<0.05 vs. C1498 injected group, n=4). WT: wild type, C1498: C1498 injected, P: peptide, M: MAZ51, A: ara-C.

Article Snippet: The murine myeloid leukemia cell line C1498 (a murine AML cell line, TIB-49; ATCC, Manassas, VA, USA) was used.

Techniques: Injection

Journal: International Journal of Stem Cells

Article Title: Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia

doi: 10.15283/ijsc21083

Figure Lengend Snippet: Combinational therapies with peptide and ara-C effectively suppress leukemia blast cells in AML mice. (A) H&E staining. BM, spleen and liver from C1498 cells injection mice showed successful engraftment of leukemia cells. Insets (magnification, ×40) show enlargement of cells within the main images (magnification, ×10). (B) Statistical analysis for the upper panel of a single treated group. And the lower panel for double-, triple treatment groups. Bars represent an average (mean)±SE, and asterisks represent statistically significant differences compared to C1498 injected group The indicated values are the averages calculated from at least 5 randomly selected fields of each group of 3 independent experiments (*p<0.05; **p<0.01; vs. C1498 injected group, n=12). C1498: C1498 injected, P: peptide, M: MAZ51, A: ara-C.

Article Snippet: The murine myeloid leukemia cell line C1498 (a murine AML cell line, TIB-49; ATCC, Manassas, VA, USA) was used.

Techniques: Staining, Injection

Journal: International Journal of Stem Cells

Article Title: Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia

doi: 10.15283/ijsc21083

Figure Lengend Snippet: Comparison of survival over time in the groups. No significant differences in the survival rate were detected between each group, however, dual and triple treated groups displayed a long life span, compared to that of C1498 groups and single only treated groups. It suggests the benefits of peptide and ara-C in AML treatment. WT: wild type, C1498: C1498 injected, P: peptide, M: MAZ51, A: ara-C.

Article Snippet: The murine myeloid leukemia cell line C1498 (a murine AML cell line, TIB-49; ATCC, Manassas, VA, USA) was used.

Techniques: Comparison, Injection

Journal: Frontiers in pharmacology

Article Title: Brg1 and RUNX1 synergy in regulating TRPM4 channel in mouse cardiomyocytes.

doi: 10.3389/fphar.2024.1494205

Figure Lengend Snippet: FIGURE 8 Brg1 modulated TRPM4 promoter activity by interaction with RUNX1. (A) Predicting the residue label and hydrogen bond length of interaction between Brg1 and RUNX1, and the combination state and surface structure of Brg1 and RUNX1 by Protein Data Bank. (B) Co-immunoprecipitation assays of Brg1 and RUNX1 on the nucleoprotein extracted from neonatal mouse cardiomyocytes. (C) RUNX1 significantly boosted TRPM4 promoter activity. Statistical analysis was performed with two-tailed Student’s t-test. *p < 0.05, **p < 0.01 vs. NC group. n = 8 in each group. (D) Brg1 knockdown significantly decreased the TRPM4 promoter activity. **p < 0.01 vs. Scramble-siRNA group by two-tailed Student’s t-test. n = 6 in each group. (E) Inhibited Brg1 by PFI-3 (10 μM) significantly reduced the TRPM4 promoter activity. **p < 0.01 vs. DMSO group by two-tailed Student’s t-test. n = 6 in each group. (F) RUNX1 knockdown declined the increases in TRPM4 promoter activity caused by Brg1-OE. *p < 0.05, vs. NC group; ##p < 0.01 vs. +Scramble-siRNA by (Continued)

Article Snippet: After incubation in 5% non-fat milk for 1.5 h at room temperature, the membranes were incubated at 4°C overnight with TRPM4 antibody (1:500; ABclonal Technology Co.,Ltd.), β-actin antibody (1:1000; Santa, United States), Brg1 antibody (Sigma-Aldrich, 07–478, 1:500) and RUNX1 antibody (Proteintech 25315-1-AP, 1:1000).

Techniques: Activity Assay, Residue, Immunoprecipitation, Two Tailed Test, Knockdown

Journal: Frontiers in pharmacology

Article Title: Brg1 and RUNX1 synergy in regulating TRPM4 channel in mouse cardiomyocytes.

doi: 10.3389/fphar.2024.1494205

Figure Lengend Snippet: FIGURE 9 A schematic diagram summarizing the potential mechanisms that Brg1 interacted with RUNX1 transcriptional regulated TRPM4, that eventually leads to TRPM4 overactivation in cardiomyocytes induced by hypoxia.

Article Snippet: After incubation in 5% non-fat milk for 1.5 h at room temperature, the membranes were incubated at 4°C overnight with TRPM4 antibody (1:500; ABclonal Technology Co.,Ltd.), β-actin antibody (1:1000; Santa, United States), Brg1 antibody (Sigma-Aldrich, 07–478, 1:500) and RUNX1 antibody (Proteintech 25315-1-AP, 1:1000).

Techniques: